US Stock Movement: Iovance Plummets on October 29 Due to Poor Lung Cancer Data and Low Efficacy for KRAS Mutation

Iovance October 29 Significant Drop Analysis

Keywords: Poor lung cancer data, low efficacy in KRAS mutations

1. On October 29, the company announced updated phase II IOV-LUN-202 data, with an objective response rate of 24.6% among 69 cases of non-squamous mNSCLC, which is basically consistent with the previous 25.6%, showing no overall improvement in efficacy; the KRAS mutation subgroup had an ORR of only 11.4%, significantly lower than the 43.3% in the KRAS wild-type group and 59.1% in the biomarker-enriched subgroup.

2. On October 29, the company indicated it would start the biomarker-enriched POSITILITY study in November 2026 and only plans to submit the sBLA in 2027, meaning the registration and commercialization milestones are still some time away.

3. After the company raised its full-year revenue guidance on September 29, the share price surged in a single day, reaching a 52-week high. As of October 29, the stock has dropped a cumulative 19.77% over the past five days but is still up 315.53% year-to-date, with ongoing profit-taking pressure following the previous rapid rise.

(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)